Strengthening a new-product development framework with global competitiveness
First written in FY2016. 3 of 8 entries say "Restated". Latest entry: FY2026.
3 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「“Priority Measures under the New Medium-Term Management Plan” ・Promotion of a growth strategy through quality culture and innovation」
The wording referring to a new product development framework with global competitiveness was reorganized under the new medium-term plan as a growth strategy combining quality culture and innovation. - 2026-05-19AdvancedManagement plan
「We will overcome the rapidly changing economic environment by simultaneously strengthening the competitiveness of our major products and actively introducing new products and technologies.」
Strengthening the competitiveness of major products and introducing new products and technologies were positioned as basic policies under the new medium-term plan, which also calls for accelerating the development of new products for electronic materials in the chemical products field. - FY2024AdvancedAnnual report
「Although sales of certain semiconductor-related products declined, sales increased 0.7% year on year to ¥12,932 million, a record high for the fifth consecutive period, driven by higher sales of new products for electronic materials and active pharmaceutical ingredients, mainly developed overseas.」
In connection with the policy of continuously introducing new products, the Company disclosed increased sales of new products for electronic materials as a factor contributing to performance. Company-wide sales reached ¥12,932 million, setting a record high for the fifth consecutive period. - FY2020ReframedAnnual report
「④ Utilization of new pharmaceutical facilities and expansion of the new product development framework We will expand sales by utilizing the new pharmaceutical facilities to strengthen our new product development framework.」
The previous policy of maintaining a new product development framework with global competitiveness has been developed into a priority measure under the medium-term plan, linked to the utilization of the new pharmaceutical facilities. - FY2019-Q1RestatedAnnual report
「An overview of the new facilities is as follows. ・Products: Pharmaceutical active ingredients and intermediates」
The products to be manufactured at the completed new pharmaceutical facilities were stated, but no new results or policy changes were indicated regarding a new product development framework with global competitiveness. - FY2018RestatedAnnual report
「Strengthening a new-product development framework with global competitiveness」
The same measure has been reiterated as a means of creating future sources of revenue. The Company also refers to strengthening its new product development framework through the construction and utilization of new pharmaceutical facilities, but no specific results have been reported. - FY2017RestatedAnnual report
「Strengthening a new-product development framework with global competitiveness」
The same policy has been reiterated as a measure to create future sources of revenue. - FY2016First statedAnnual report
「Strengthening a new-product development framework with global competitiveness」
Presents strengthening the new-product development framework as a measure to create future sources of revenue.